A phase 2 trial of a “sandwich” strategy: Sequential CD22/CD19 chimeric antigen receptor T‐cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome–negative B‐cell acute lymphoblastic leu
The CD22/CD19 CAR T-cell and auto-HSCT sandwich strategy represents a promising approach for the treatment of Ph-negative B-ALL in AYA and adult patients, offering high efficacy and a favorable safety profile. The trial registration is ClinicalTrials.gov identifier NCT05470777.
Authors
- Shengli Xue (ORCID: https://orcid.org/0000-0003-4609-616X)
- Han‐Yu Cao (ORCID: https://orcid.org/0000-0003-3022-6935)
- Haiping Dai (ORCID: https://orcid.org/0000-0003-1125-7744)
- Shuang Xu (ORCID: https://orcid.org/0009-0005-7321-221X)
- Yan Qiu (ORCID: https://orcid.org/0000-0003-1291-5892)
- Zhen Yao (ORCID: https://orcid.org/0000-0001-8369-843X)
- F.-J. Liu (ORCID: https://orcid.org/0009-0005-1260-7293)
- Zheng Li (ORCID: https://orcid.org/0000-0001-6024-0194)
- Depei Wu (ORCID: https://orcid.org/0000-0002-6312-3863)
- Haixia Zhou (ORCID: https://orcid.org/0009-0001-5309-5715)
- Kaiwen Tan
- Si‐Man Huang
- Wenjie Gong (ORCID: https://orcid.org/0000-0001-6965-6209)
- Yanjun Wu (ORCID: https://orcid.org/0009-0007-4954-8658)
- Mingzhu Xu
Institutions
- Soochow University (CN)
- The First People's Hospital of Changzhou (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Cancer
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1002/cncr.70168
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- Soochow University